161 results
Page 5 of 9
8-K
EX-99.1
z7ajnm
14 Jan 21
Results of Operations and Financial Condition
8:30am
8-K
yyh5lx8l5l
21 Sep 20
Regulation FD Disclosure
4:10pm
8-K
EX-1.1
5rsx w4rdd8ao1vtxcxb
21 Feb 20
Agile Therapeutics Announces Proposed Underwritten Public Offering of Common Stock
4:46pm
424B5
767 4axwvdnz0ju
21 Feb 20
Prospectus supplement for primary offering
4:26pm
424B5
syxy94fafj4l1s6w
20 Feb 20
Prospectus supplement for primary offering
5:28pm
8-K
EX-10.1
q0727t0965oe0b598
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-4.1
9foertzcq81sl1jtf
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-4.2
n4o9vi
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-99.1
fhzoz
12 Feb 20
Entry into a Material Definitive Agreement
8:00am
8-K
EX-99.1
2jna3ydi53v3
8 Jan 20
Results of Operations and Financial Condition
4:31pm
8-K
EX-99.1
exwhfnfb12zz8
14 Nov 19
Agile Therapeutics Announces FDA Extension of Twirla® NDA Review Period
4:38pm
8-K
EX-1.1
b4y5xi37mgm5pv
8 Nov 19
Entry into a Material Definitive Agreement
4:38pm